Tirzepatide 30mg: what the evidence actually says

Step 1: understanding how the licensed dose schedule works

Mounjaro's treatment pathway is a gradual, prescriber-guided climb. It starts at 2.5mg (a dose whose job is to let your body adjust, not to drive weight loss) and moves through 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg. Each step typically takes around four weeks before a prescriber reviews whether you're tolerating the current level and progressing as expected. The ceiling is 15mg. There is no 30mg rung on this ladder.

That structure is deliberate. The gastrointestinal side effects that tirzepatide can cause (nausea, constipation, indigestion) are most pronounced when the dose changes. A slow ascent gives your system time to settle at each level. Jumping to a dose twice the maximum licensed strength wouldn't speed things up; it would almost certainly cause significant harm.

The NICE appraisal of tirzepatide (TA1026) and the Mounjaro Summary of Product Characteristics both base their recommendations on the 2.5–15mg schedule used in the SURMOUNT clinical programme. That's the evidence base. A 30mg dose was not part of those trials.

Step 2: where the phrase "30mg tirzepatide" actually comes from

The term surfaces in a couple of distinct contexts, and it's worth being clear about each one.

The first is compounded tirzepatide, preparations mixed by a pharmacy from bulk active ingredient, sometimes described in milligram quantities that don't match the Mounjaro schedule. In the US, compounded tirzepatide has been widely discussed; it has no equivalent licensed product in the UK, and the MHRA has not authorised compounded tirzepatide for weight management here.

The second is reconstituted peptide preparations sold online, and pages describing 30mg 3ml tirzepatide vials are a common example of this category. These are not the same as Mounjaro. They are not MHRA-licensed medicines. They arrive as powders or liquids requiring mixing, which introduces real risks around sterility and dosing accuracy. The MHRA has warned about fake and unlicensed weight-loss preparations circulating online, and reports of harm from unverified sources have been well documented. You can report a suspect seller at Yellow Card.

If you've been exploring how reconstituted 30mg tirzepatide works, it's worth understanding that this sits entirely outside the licensed, regulated pathway, and with it, outside any clinical safety net.

Step 3: what the licensed 15mg actually delivers

The SURMOUNT-1 trial (involving over 2,500 adults with obesity, run over 72 weeks) found that participants on 15mg tirzepatide lost around 20–21% of their body weight on average. That's a substantial result, reported in the New England Journal of Medicine and the foundation for NICE's recommendation. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks.

There's no evidence that going beyond 15mg would improve on those outcomes, and if you've come across references to Mounjaro 30mg, it's important to know that no such licensed product exists and the clinical case for staying within the regulated range is straightforwardly compelling once you see what 15mg can do. The dose-response curve for GLP-1 and GIP receptor agonists doesn't simply scale upward; side effects do.

If you're thinking about cost at the higher doses, the real picture of Mounjaro pricing in the UK is worth reading before drawing any conclusions about whether unlicensed alternatives represent value.

Step 4: what this means if you're considering treatment

The conversation about 30mg of tirzepatide is, for most people, a dead end, but it often starts because someone genuinely wants effective treatment and has been told by a forum or a seller that higher means better. That's understandable. The good news is that the licensed pathway is genuinely effective, and access through a GPhC-registered pharmacy is more straightforward than many people expect.

Eligibility for licensed tirzepatide (Mounjaro) in the UK is based on BMI (30 or above, or 27 or above with a weight-related health condition such as high blood pressure, type 2 diabetes or high cholesterol). Lower thresholds apply for some ethnic backgrounds under UK guidance. A prescriber reviews the full picture: current health, medicines, history. The BMI figure opens the door; clinical judgement decides whether treatment is right for you.

Our clinical team at nume reviews every consultation personally, a real prescriber reads your answers the same day, not software. If you order before 12pm on a weekday, an approved treatment is dispatched the same day and delivered free the next working day by DPD, in plain packaging. You can find out more about how the process works on our tirzepatide overview page, or read about Mounjaro specifically and the full licensed dose range.

For a broader look at all available options, our weight-loss treatment overview sets out what's currently licensed in the UK and how each medicine works. When you're ready, check your eligibility with a free consultation, there's no commitment, and a prescriber will tell you honestly whether treatment is suitable.